AstraZeneca interested in Russian molecules for oncology
AstraZeneca, a British-Swedish biopharmaceutical multinational, is interested in new molecules by Russian developers and considering investing more than $16m in an effort to localize production in the Russian Federation, the Skolkovo Foundation website announced, citing a recent statement by AstraZeneca CEO Pascal Soriot.